Review explores how genetic advances are reshaping SM diagnosis and treatment
A new review underscores how genetic research is transforming the diagnosis and management of systemic mastocytosis.
A new review underscores how genetic research is transforming the diagnosis and management of systemic mastocytosis.
A rare presentation of systemic mastocytosis (SM) alongside postural orthostatic tachycardia syndrome (POTS) was recently reported.
A new study explores the diagnostic challenges posed by SM with an associated myeloid neoplasm (SM-AMN), an advanced form of SM.
Midostaurin is safe and effective in treating advanced systemic mastocytosis.
A new case study from New Zealand sheds light on diagnostic and treatment challenges for aggressive systemic mastocytosis in newborns
Flow-SuperRCA is a new, ultra-sensitive test to detect the D816V KIT mutation in patients with SM and other mast cell conditions.
A woman with difficulty swallowing and weight loss was initially thought to have a gastrointestinal condition, but was later diagnosed with SM.
Well-differentiated systemic mastocytosis (WDSM), a rare SM variant, was recently associated with previously unknown genetic mutations.
Drug-induced reactions such as anaphylaxis are possible in patients with SM, but recent data suggests that the risk is relatively low.
SM is a risk factor for the development of respiratory symptoms, regardless of whether it presents as indolent SM or advanced SM.